🚀 VC round data is live in beta, check it out!
Hyundai Bioscience Valuation Multiples
Discover revenue and EBITDA valuation multiples for Hyundai Bioscience and similar public comparables like Compass Therapeutics, MeiraGTx, AprilBio, Omeros and more.
Hyundai Bioscience Overview
About Hyundai Bioscience
Hyundai Bioscience Co Ltd is a Korean biotechnology company. The company is engaged in developing and commercializing bio-fusion technology with the purpose of delivering active ingredients safely and efficiently to the body. It has developed Vitabrid CG, a biomaterial that binds vitamin C with bio-friendly mineral layers, which is a beneficial ingredient in skin brightening, anti-aging, and anti-inflammation; and Vitabrid C12, a premium skincare brand.
Founded
2005
HQ
Employees
N/A
Website
Sectors
Financials (FY)
EV
$962M
Hyundai Bioscience Financials
Hyundai Bioscience reported last fiscal year revenue of $2M and negative EBITDA of ($13M).
In the same fiscal year, Hyundai Bioscience generated $166K in gross profit, ($13M) in EBITDA losses, and had net loss of ($15M).
Hyundai Bioscience P&L
In the most recent fiscal year, Hyundai Bioscience reported revenue of $2M and EBITDA of ($13M).
Hyundai Bioscience expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $2M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $166K | XXX | XXX | XXX |
| Gross Margin | — | XXX | 7% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($13M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (522%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (516%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($15M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (629%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Hyundai Bioscience Stock Performance
Hyundai Bioscience has current market cap of $977M, and enterprise value of $962M.
Market Cap Evolution
Hyundai Bioscience's stock price is $10.18.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $962M | $977M | 3.5% | XXX | XXX | XXX | $-0.16 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialHyundai Bioscience Valuation Multiples
Hyundai Bioscience trades at 400.8x EV/Revenue multiple, and (76.8x) EV/EBITDA.
Hyundai Bioscience Financial Valuation Multiples
As of April 21, 2026, Hyundai Bioscience has market cap of $977M and EV of $962M.
Equity research analysts estimate Hyundai Bioscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Hyundai Bioscience has a P/E ratio of (64.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $977M | XXX | $977M | XXX | XXX | XXX |
| EV (current) | $962M | XXX | $962M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 400.8x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (76.8x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (77.6x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 5786.0x | XXX | XXX | XXX |
| P/E | — | XXX | (64.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (37.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Hyundai Bioscience Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Hyundai Bioscience Margins & Growth Rates
Hyundai Bioscience's revenue in the last fiscal year declined by (77%).
Hyundai Bioscience Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (77%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (522%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 361% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 133% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 21% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 216% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 523% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Hyundai Bioscience Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Hyundai Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| Compass Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| MeiraGTx | XXX | XXX | XXX | XXX | XXX | XXX |
| AprilBio | XXX | XXX | XXX | XXX | XXX | XXX |
| Omeros | XXX | XXX | XXX | XXX | XXX | XXX |
| Kaken Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hyundai Bioscience M&A Activity
Hyundai Bioscience acquired XXX companies to date.
Last acquisition by Hyundai Bioscience was on XXXXXXXX, XXXXX. Hyundai Bioscience acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Hyundai Bioscience
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialHyundai Bioscience Investment Activity
Hyundai Bioscience invested in XXX companies to date.
Hyundai Bioscience made its latest investment on XXXXXXXX, XXXXX. Hyundai Bioscience invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Hyundai Bioscience
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Hyundai Bioscience
| When was Hyundai Bioscience founded? | Hyundai Bioscience was founded in 2005. |
| Where is Hyundai Bioscience headquartered? | Hyundai Bioscience is headquartered in South Korea. |
| Who is the CEO of Hyundai Bioscience? | Hyundai Bioscience's CEO is Sang-Gi Oh. |
| Is Hyundai Bioscience publicly listed? | Yes, Hyundai Bioscience is a public company listed on Korea Exchange. |
| What is the stock symbol of Hyundai Bioscience? | Hyundai Bioscience trades under 048410 ticker. |
| When did Hyundai Bioscience go public? | Hyundai Bioscience went public in 2002. |
| Who are competitors of Hyundai Bioscience? | Hyundai Bioscience main competitors are Compass Therapeutics, MeiraGTx, AprilBio, Omeros. |
| What is the current market cap of Hyundai Bioscience? | Hyundai Bioscience's current market cap is $977M. |
| What is the current revenue of Hyundai Bioscience? | Hyundai Bioscience's last fiscal year revenue is $2M. |
| What is the current EV/Revenue multiple of Hyundai Bioscience? | Current revenue multiple of Hyundai Bioscience is 400.8x. |
| Is Hyundai Bioscience profitable? | No, Hyundai Bioscience is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.